Related Experiment Video
Updated: Feb 7, 2026
06:19
Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
Published on: May 16, 2025
1.5K
Anti-Integrin αvβ6 Autoantibodies Predict Response and Treatment Persistence to Advanced Therapies in Ulcerative
Shunsuke Shibui1,2, Kunio Asonuma1, Satoshi Kuronuma3
1Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan.
Clinical and Translational Gastroenterology
|February 5, 2026
Summary
Anti-integrin αvβ6 autoantibodies predict treatment success in ulcerative colitis. Lower antibody levels are linked to better treatment persistence and higher remission rates, identifying them as a key predictive biomarker.
Area of Science:
- Gastroenterology
- Immunology
- Biomarker Discovery
Background:
- Anti-integrin αvβ6 (anti-αvβ6) autoantibodies are diagnostic biomarkers in ulcerative colitis (UC) and associated with poor prognosis.
- Their role in predicting treatment outcomes for advanced therapies in UC requires further investigation.
Purpose of the Study:
- To investigate if anti-αvβ6 autoantibody levels predict treatment persistence and clinical remission in patients with moderately to severely active UC receiving advanced therapies.
Main Methods:
- Prospective measurement of anti-αvβ6 autoantibody levels at advanced therapy initiation.
- Assessment of treatment persistence (primary outcome) and clinical remission rates (secondary outcomes) up to 48 weeks.
- Stratification into low- and high-level antibody groups using receiver operating characteristic analysis.
Main Results:
- Treatment persistence was significantly higher in the low anti-αvβ6 antibody group (p = 0.002).
- Low antibody levels were the sole independent predictor of treatment persistence (HR, 1.90).
- Clinical remission rates were consistently higher in the low-level group, particularly at week 6 (47.5% vs. 20.0%; p = 0.003).
Conclusions:
- Anti-αvβ6 autoantibodies serve as a predictive biomarker for treatment persistence and clinical remission in advanced therapies for active UC.
- These findings highlight the potential utility of anti-αvβ6 autoantibodies in guiding treatment decisions for UC patients.
Keywords:
advanced therapiesanti-integrin αvβ6 autoantibodiesbiomarkertreatment outcomeulcerative colitisMore Related Videos
04:09Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
Published on: October 10, 2018
8.8K
10:55Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy
Published on: October 31, 2025
846
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
527
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
527
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
1.0K
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
1.0K
01:10Integrins
5.5K
Animal and protozoan cells do not have cell walls to help maintain shape and provide structural stability. Instead, these eukaryotic cells secrete a sticky mass of carbohydrates and proteins into the spaces between adjacent cells. This network of proteins and molecules is called an extracellular matrix or ECM.
Some ECM proteins assemble into a basement membrane to which the remaining components adhere. Proteoglycans typically form the bulk of the ECM while fibrous proteins, like collagen,...
Some ECM proteins assemble into a basement membrane to which the remaining components adhere. Proteoglycans typically form the bulk of the ECM while fibrous proteins, like collagen,...
5.5K
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
1.3K
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
1.3K
01:15Activation of Integrins
5.1K
Integrins bind ligands and transmit information from outside the cell to inside or vice-versa through an "outside-in signaling" or "inside-out signaling."
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding...
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding...
5.1K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
568
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
568